Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Tirzepatide
CAS: 2023788-19-2
El agonista dual más estudiado para la reducción de peso
Tirzepatide es un péptido de investigación en la categoría de GLP-1 / control de peso. Tirzepatide es un agonista dual de los receptores GIP y GLP-1 que activa ambas vías de incretinas simultáneamente. MiPeptidos ofrece Tirzepatide en 10 tamaños con 99.2% de pureza verificada y documentación analítica completa.
- Supresión superior del apetito
- Pérdida de peso más rápida que los GLP-1
- Mejor sensibilidad a la insulina
- Reducción del perímetro de cintura
Los estudios sugieren que la reducción del apetito comienza dentro de la primera semana, a menudo de manera más notable que con péptidos de una sola vía. Entre las semanas 4-8, los estudios reportan una pérdida de peso consistente que se acelera a 1-1.5 kg por semana a medida que aumenta la dosis. Los ensayos clínicos mostraron que los participantes perdieron más del 20% de su peso corporal en la semana 72, con muchos notando cambios drásticos en cómo les queda la ropa en la semana 12. Tirzepatide activa dos vías del hambre a la vez, por lo que los resultados tienden a superar las opciones de objetivo único.
$16.80/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Dual-Action Weight Loss.
20-week dual-incretin protocol backed by SURPASS and SURMOUNT trials with 20,000+ participants
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that activates both incretin pathways simultaneously, achieving weight loss outcomes that surpass any single-receptor GLP-1 agonist. Developed by Eli Lilly, it is approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), with landmark SURMOUNT-1 data showing an unprecedented 22.5% mean weight loss at the highest dose.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Ania Jastreboff
Director, Yale Obesity Research Center
Associate Professor of Medicine and Pediatrics at Yale School of Medicine. Lead investigator of SURMOUNT-1, the pivotal tirzepatide obesity trial. MD, PhD.
The degree of weight reduction with tirzepatide is remarkable — more than 20% mean body weight loss — and brings us closer to what we see with bariatric surgery.
Gradual dose escalation from 2.5mg to 15mg over 20 weeks is critical for GI tolerability. Tirzepatide should be viewed as long-term therapy, not a short course.
Fuente: SURMOUNT-1 (NEJM, 2022); Yale Medicine interviews
Dr. Peter Attia
Physician, Founder of Attia Medical PC
MD from Stanford. Host of 'The Drive,' one of the most influential health podcasts. Author of 'Outlive: The Science and Art of Longevity.' Specialist in longevity medicine.
Tirzepatide may be superior to semaglutide because of its dual GIP/GLP-1 targeting. The SURPASS-2 data showing it nearly doubled semaglutide's weight loss at comparable doses is striking.
Pair with high protein intake (1g/lb lean mass) and resistance training 3x/week. Monitor DEXA body composition every 12 weeks to ensure lean mass preservation.
Fuente: The Peter Attia Drive Podcast: AMA #45, AMA #64
Dr. Juan Pablo Frías
Medical Director, National Research Institute, Los Angeles
Lead investigator in SURPASS-1 and SURMOUNT-2 trials. One of the most prolific clinical trialists in GLP-1 and dual-agonist research.
Tirzepatide at the 15mg dose produced HbA1c reductions that brought the majority of patients with type 2 diabetes to below 5.7% — essentially a non-diabetic level.
Start at 2.5mg weekly for 4 weeks minimum. Do not escalate if GI symptoms are unresolved. The 5mg to 10mg transition is where most GI events occur.
Fuente: SURPASS-1 (NEJM, 2021, PMID: 34170647); SURMOUNT-2 (Lancet, 2023)
Dr. Fatima Cody Stanford
Obesity Medicine Physician, Massachusetts General Hospital
Associate Professor at Harvard Medical School. Director of scholarly engagement, Nutrition Obesity Research Center at Harvard. MD, MPH, MPA, MBA.
Tirzepatide represents a paradigm shift. Dual-incretin agonism provides metabolic benefits that go beyond what a GLP-1 agonist alone can achieve.
Emphasizes that obesity is a chronic disease requiring long-term pharmacotherapy. Tirzepatide should be combined with nutritional counseling and physical activity for optimal outcomes.
Fuente: Harvard Magazine (2024); CBS 60 Minutes commentary
Protocolo de Dosificación
4 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Starting dose for GI tolerability assessment. Not a therapeutic dose — purely for adaptation. Nausea occurs in ~12-18% at this level. Inject on the same day each week.
First therapeutic dose. Appetite suppression becomes noticeable. Some protocols maintain here for additional 4 weeks if GI symptoms persist before escalating.
Significant metabolic effects at this dose. SURMOUNT-1 showed 20.0% weight loss at 10mg. This is the most common dose where GI events spike — escalate slowly.
Maximum studied dose. SURMOUNT-1 peak: 22.5% weight loss at 72 weeks. Maintain long-term — significant weight regain occurs upon discontinuation.
Research-grade lyophilized tirzepatide: reconstitute 5mg vial with 1mL bacteriostatic water = 5mg/mL. For 2.5mg dose = 0.5mL (50 units on insulin syringe). For 5mg dose = 1.0mL. Calculate carefully based on vial size and desired concentration.
Tirzepatide is designed for continuous long-term use, not cycled. SURMOUNT-3 showed weight regain upon withdrawal. If discontinuing, taper gradually: step down one dose level every 4 weeks to minimize rebound weight gain and GI distress.
Lyophilized: store at -20°C for long-term, 2-8°C for short-term. Reconstituted: refrigerate at 2-8°C, use within 30 days. Protect from light. Do not freeze reconstituted solution.
Subcutaneous injection only. Rotate injection sites (abdomen, thigh, upper arm) each week. Inject on the same day weekly — timing of day does not matter. If a dose is missed, administer within 4 days; if more than 4 days late, skip and resume normal schedule.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
GI Adaptation & Receptor Priming
- Dual GIP/GLP-1 receptor engagement begins — both incretin pathways activated
- Mild appetite reduction as hypothalamic GLP-1R signaling initiates
- GI adaptation period — nausea in 12-18% at 2.5mg starting dose
- Glucose-dependent insulin secretion enhanced via both receptor pathways
- Typical weight loss: 1-3% of body weight
Base de investigación: SURPASS-1 (Rosenstock et al., 2021, NEJM, PMID: 34170647)
Dose Escalation & Accelerating Metabolic Effects
- Escalation from 5mg to 10mg drives significant appetite suppression
- Fasting insulin and glucose levels measurably improved
- GIP-mediated insulin sensitivity improvements become apparent
- GI side effects peak during 5→10mg transition, then stabilize
- Typical weight loss: 8-12% of body weight
Base de investigación: SURPASS-2 (Frías et al., 2021, NEJM, PMID: 34170646); SURMOUNT-1 (PMID: 35658024)
Peak Dose & Maximum Metabolic Response
- 15mg target dose reached — full dual-agonist effects
- HbA1c reductions of 2.0-2.4% bring most T2D patients below 5.7%
- Visceral fat preferentially reduced alongside subcutaneous fat
- Blood pressure, triglycerides, and inflammatory markers significantly improved
- Typical weight loss: 15-18% of body weight
Base de investigación: SURMOUNT-1 (Jastreboff et al., 2022, NEJM, PMID: 35658024)
Sustained Loss & Long-Term Maintenance
- Weight loss continues to progress through week 72
- SURMOUNT-1: 22.5% mean weight loss at 15mg at 72 weeks
- 39.7% of participants lost ≥25% body weight at highest dose
- Cardiovascular risk factor improvements sustained with ongoing treatment
- Discontinuation leads to significant weight regain — ongoing therapy recommended
Base de investigación: SURMOUNT-1 (PMID: 35658024); SURMOUNT-3 withdrawal data
Mecanismo de Acción
4 vías biológicas distintas a través de las cuales opera este péptido.
Dual GIP/GLP-1 Receptor Agonism
Simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, providing synergistic metabolic effects beyond either pathway alone.
- GIP receptor activation enhances insulin sensitivity in adipose tissue and promotes lipid metabolism
- GLP-1 receptor activation drives appetite suppression and glucose-dependent insulin secretion
- Biased agonism at GIP receptor preferentially activates cAMP over beta-arrestin pathways
- Dual pathway engagement explains superior efficacy over pure GLP-1 agonists like semaglutide
Frías et al. (2021) SURPASS-2 (PMID: 34170646); Willard et al. (2020) Mol Metab
Hypothalamic Appetite & Satiety Control
Acts on GLP-1 receptors in the hypothalamus and brainstem to upregulate satiety pathways and downregulate hunger drive, with additional GIP-mediated effects on food reward circuitry.
- Upregulates POMC/CART anorexigenic pathway — signals to eat less
- Downregulates NPY/AgRP orexigenic pathway — reduces hunger drive
- GIP receptor activation in brain may modulate reward-based eating behavior
- Patients report reduced food noise and decreased cravings within first 4-8 weeks
SURMOUNT-1 (PMID: 35658024); Samms et al. (2020) J Clin Invest
Enhanced Insulin Sensitivity & Beta-Cell Function
Improves both insulin secretion and peripheral insulin sensitivity through complementary GIP and GLP-1 pathways, achieving glycemic normalization in a majority of T2D patients.
- GLP-1R activation enhances glucose-dependent insulin secretion from beta cells
- GIP-R activation improves insulin sensitivity in adipose tissue and muscle
- Combined effect reduces HbA1c by 2.0-2.4% — bringing most T2D patients to non-diabetic levels
- Beta-cell preservation effects demonstrated in preclinical models
SURPASS-1 (PMID: 34170647); SURPASS-2 (PMID: 34170646)
Lipid Metabolism & Visceral Fat Reduction
GIP receptor activation in adipose tissue directly modulates lipid storage and mobilization, preferentially reducing visceral and hepatic fat depots.
- GIP receptors on adipocytes regulate triglyceride storage and fatty acid uptake
- Visceral fat preferentially reduced — improving metabolic syndrome parameters
- Liver fat content significantly reduced, with MASH/NASH improvements observed
- Triglyceride reductions of 25-35% observed in SURPASS trials
SURMOUNT-1 substudy; Samms et al. (2020) J Clin Invest
Investigación Publicada
6 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. — New England Journal of Medicine (2022)
Hallazgo Clave: SURMOUNT-1: Tirzepatide 15mg produced 22.5% mean weight loss at 72 weeks (n=2,539). 39.7% lost ≥25% body weight. Unprecedented for a pharmacological intervention.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al. — New England Journal of Medicine (2021)
Hallazgo Clave: Head-to-head: tirzepatide 15mg achieved 2.4% HbA1c reduction vs 1.9% for semaglutide 1mg, and 13.1% weight loss vs 6.7%. Nearly double the weight loss.
Tirzepatide Once a Week for the Treatment of Type 2 Diabetes (SURPASS-1)
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. — New England Journal of Medicine (2021)
Hallazgo Clave: SURPASS-1: Tirzepatide monotherapy reduced HbA1c by 2.07% at 15mg dose. 87-92% of patients achieved HbA1c <7%, and 23-62% reached ≤5.7% (non-diabetic range).
Tirzepatide for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al. — The Lancet (2023)
Hallazgo Clave: SURMOUNT-2: In T2D patients, tirzepatide 15mg achieved 14.7% weight loss at 72 weeks, with 40% losing ≥15% body weight. HbA1c reduced by 2.1%.
Tirzepatide versus insulin lispro added to basal insulin in type 2 diabetes (SURPASS-6)
Rosenstock J, Frías JP, Rodbard HW, Tofé S, Sears E, Huh R, et al. — JAMA (2023)
Hallazgo Clave: Tirzepatide 15mg reduced HbA1c by 2.1% and body weight by 10.5kg vs weight gain with insulin lispro. Demonstrates glycemic control with weight loss rather than weight gain.
Efficacy and safety of tirzepatide monotherapy vs placebo in Japanese patients (SURPASS J-mono)
Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. — Diabetes, Obesity and Metabolism (2023)
Hallazgo Clave: Confirmed tirzepatide efficacy in East Asian population. HbA1c reduction of 2.4% and body weight loss of 7.0kg at 15mg over 52 weeks in Japanese patients.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Tirzepatide con estos péptidos para mecanismos complementarios.
Rotating between tirzepatide and semaglutide may help overcome plateaus by varying receptor activation profiles.
NOTE: These are alternatives, not combined simultaneously. Switching from semaglutide to tirzepatide is a common clinical upgrade pathway when weight loss plateaus.
BPC-157 provides GI mucosal protection that can mitigate tirzepatide's common GI side effects during dose escalation.
May reduce GI discontinuation rates during the critical 5-10mg escalation phase where side effects peak. BPC-157's acid stability makes it ideal for GI protection.
Growth hormone secretagogues help preserve lean muscle mass during rapid weight loss from tirzepatide.
Addresses the primary concern with potent weight loss agents: preserving metabolically active lean tissue during aggressive caloric deficit.
AOD-9604 may enhance fat-specific metabolism through HGH fragment pathways, complementing tirzepatide's appetite-mediated approach.
Theoretical synergy: tirzepatide handles caloric reduction while AOD-9604 may target stubborn adipose tissue directly. Limited clinical evidence for the combination.
Especificaciones
Cómo Funciona Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. It stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, and reduces appetite via central and peripheral signaling. The dual receptor engagement provides synergistic metabolic effects beyond GLP-1 agonism alone, including enhanced lipid metabolism and improved insulin sensitivity.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
2mg | $100.00 | $850.00 | — |
5mg | $120.00 | $1020.00 | — |
10mg | $224.95 | $191.95 | — |
15mg | $299.95 | $254.95 | — |
20mgOferta | $275.95$310.00 | $2345.57 | 11% descuento |
30mgOferta | $111.95$280.00 | $951.57 | 60% descuento |
40mg | $320.00 | $2720.00 | — |
50mg | $360.00 | $3060.00 | — |
60mgOferta | $625.95$749.95 | $5320.57 | 17% descuento |
80mgMejor Valor | $500.00 | $4250.00 | — |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved in research peptide form
Only branded Mounjaro (T2D) and Zepbound (obesity) are FDA-approved. Research-grade tirzepatide peptide is not approved for human use. All information is for research and educational purposes only.
Thyroid C-cell tumors (Boxed Warning)
In rodents, tirzepatide causes thyroid C-cell tumors. CONTRAINDICATED in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis risk
Acute pancreatitis has been reported with GLP-1-based therapies including tirzepatide. Discontinue immediately if persistent severe abdominal pain occurs. Do not restart after confirmed pancreatitis.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 50% OffSemaglutide
Estudiado clínicamente para una reducción de peso constante — una vez por semana
Up to 42% OffRetatrutide
Agonista de triple receptor estudiado para una actividad metabólica mejorada
Up to 38% OffLiraglutide
GLP-1 diario estudiado para la regulación constante del apetito
Up to 15% OffCagrilintide
Estudiado para vías de saciedad mediadas por amilina más allá del GLP-1